17p Deletion, Cancer of the Blood and Bone Marrow, Chronic Lymphocytic Leukemia
Conditions
Keywords
Chronic Lymphocytic Leukemia, 17p Deletion
Brief summary
This was an open-label, multicenter, global study to determine the efficacy of ABT-199 (Venetoclax) monotherapy in participants with relapsed/refractory (R/R) or previously untreated chronic lymphocytic leukemia (CLL) harboring 17p deletion.
Detailed description
This study was designed to enroll approximately 150 participants in 2 cohorts: a main cohort of approximately 100 participants, and a safety expansion (SE) cohort of approximately 50 participants. The primary objective of the main cohort was to evaluate the efficacy of ABT-199 monotherapy in participants with R/R CLL harboring the 17p deletion. The primary objective of the safety expansion cohort was to evaluate the safety of ABT-199 in approximately 50 participants with R/R CLL harboring 17p deletion treated per updated tumor lysis syndrome (TLS) prophylaxis and management measures.
Interventions
DRUGABT-199 (Main Cohort)
Participants received a test dose of ABT-199 of ≤ 20 mg on Week 1 Day 1 of the Lead-In Period. For those with significant electrolyte and/or lymphocyte changes within 24 hours of the first dose, the 20 mg dose was maintained for 7 days with escalation to 50 mg on Week 2 Day 1. If none of the electrolyte and/or lymphocyte changes occurred within 24 hours from ABT-199 20 mg dose administration, the participant was dose-escalated to 50 mg on Week 1 Day 2. After the first dose of 50 mg, if no laboratory abnormalities occurred, the participant remained on the 50 mg dose through Week 1. After receiving the 50 mg dose for approximately 1 week (6 to 7 days), the following dose escalation proceeded with weekly increases in dose: → 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose), as tolerated.
DRUGABT-199 (Safety Expansion Cohort)
Participants received an initial dose of ABT-199 of 20 mg on Week 1 Day 1 of the Lead-In Period. If one or more electrolyte changes (from the 0 hr measurement prior to dosing) suggestive of laboratory tumor lysis syndrome (LTLS) or clinical TLS (CTLS) occurred within 24 hours of the 20 mg dose, no additional doses were administered until resolution. Upon resolution of laboratory abnormalities, the 20 mg dose was continued through Week 1. If no significant findings suggestive of clinical or laboratory TLS occurred within 24 hours, the 20 mg dose was continued through Week 1 Day 7, and escalated to a dose of 50 mg on Week 2 Day 1. Those who had drug interruptions may have been allowed to escalate to and be maintained at 50 mg for 1 week after they had been on a 20 mg dose for at least 1 week (5 - 7 days). After a week at 50 mg, weekly dose escalations were implemented as follows: 100 mg → 200 mg → 400 mg (or additional lead-in steps to designated 400 mg dose) as tolerated.
Sponsors
Genentech, Inc.
AbbVie
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Participant must be greater than or equal to 18 years of age. * Participant must have diagnosis of chronic lymphocytic leukemia (CLL) that meets published 2008 Modified IWCLL NCI-WG (International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group) Guidelines. * Participant has an indication for treatment according to the 2008 Modified IWCLL NCI WG Guidelines; * Participant has clinically measurable disease (lymphocytosis \> 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam); * Participant must be refractory or have relapsed after receiving at least one prior line of therapy (participants that have progressed after 1 cycle of treatment or have completed at least 2 cycles of treatment for a given line of therapy) or previously untreated CLL (previously untreated CLL participants must have received no prior chemotherapy or immunotherapy. Participants with a history of emergency, loco-regional radiotherapy (e.g., for relief of compressive signs or symptoms) are eligible. In addition, participants must meet the CLL diagnostic criteria above and must have \> 5 × 10\^9/L B-Lymphocytes in the peripheral blood.); * Participants must have 17p deletion, assessed by local laboratory (in bone marrow or peripheral blood) or assessed by central laboratory (peripheral blood). * Participant has an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2. * Participant must have adequate bone marrow function at Screening as follows: * Absolute Neutrophil Count (ANC) greater than or equal to 1000/µL, or * For subjects with an ANC less than 1000/µL at Screening and bone marrow heavily infiltrated with underlying disease (unless cytopenia is clearly due to marrow involvement of CLL), growth factor support may be administered after Screening and prior to the first dose of ABT-199 to achieve the ANC eligibility criteria (greater than or equal to 1000/µL); * Platelets greater than 30,000/mm\^3 (without transfusion support within 14 days of Screening, without evidence of mucosal bleeding, without known history of bleeding episode within 3 months of Screening, and without history of bleeding disorder); * Hemoglobin greater than or equal to 8.0 g/dL. * Participant must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening as follows: * Activated partial thromboplastin time (aPTT) and prothrombin time (PT) not to exceed 1.5 × the upper limit of normal; * Calculated creatinine clearance greater than 50 mL/min using 24-hour Creatinine Clearance or modified Cockcroft-Gault equation (using Ideal Body Mass \[IBM\] instead of Mass). For participants that have body mass index (BMI) of \> 30 kg/m\^2 or \< 19 kg/m\^2, 24-hour measured urine creatinine clearance is required; * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3.0 × the upper normal limit of institution's normal range; Bilirubin less than or equal to 1.5 × upper limit of normal. Participants with Gilbert's Syndrome may have a bilirubin greater 1.5 × upper limit of normal, per correspondence between the investigator and AbbVie medical monitor. * For participants at high risk of tumor lysis syndrome a pre-approval by the AbbVie medical monitor is required prior to enrollment.
Exclusion criteria
* Participant has undergone an allogeneic stem cell transplant. * Participant has developed Richter's transformation confirmed by biopsy. * Participant has prolymphocytic leukemia. * Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose corticosteroids. * Participant has previously received ABT-199. * Participant has received a biologic agent for anti-neoplastic intent within 30 days prior to the first dose of study drug. * Participant has received any of the following within 14 days or 5 half-lives as applicable prior to the first dose of study drug, or has not recovered to less than Common Toxicity Criteria (CTC) grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy: * Any anti-cancer therapy including chemotherapy, or radiotherapy; * Investigational therapy, including targeted small molecule agents. * Participant has known allergy to both xanthine oxidase inhibitors and rasburicase.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (Main Cohort) | Up to 36 weeks | The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria as assessed by the Independent Review Committee (IRC) in the first 70 participants treated in the Main Cohort. |
| Number of Participants With Adverse Events (Safety Expansion Cohort) | From the first dose of study drug until 30 days following last dose of study drug (up to 69 months) | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Partial Remission (PR) Rate | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | PR rate was defined as the proportion of participants who achieved a nodular partial remission (nPR) or PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a nPR or PR were considered to be non-responders in the calculation of PR rate. |
| Duration of Overall Response | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Duration of overall response (DoR) was defined as the number of days from the date of first response (CR, CRi, nPR, or PR) by either CT scan or physical exam determination to the earliest recurrence (progressive disease; PD) or death. For participants who had a PR before CR, CRi, or nPR in subsequent visits, the DoR was computed from the earliest PR. If a participant was still responding, then their data was censored at the date of their last available disease assessment. To be included in the DoR analysis, participants must have had a response per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria (CR, CRi, confirmed nPR, or confirmed PR). For participants who never experienced response, their data was not included in the analysis. |
| Progression-free Survival | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Duration of progression-free survival (PFS) was defined as the number of days from the date of first dose to the date of earliest disease progression or death. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant does not experience disease progression or death, then the data was censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day. |
| Event-free Survival | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Event-free survival (EFS) was defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy. If the specified event (disease progression, death, start of a new anti-leukemic treatment) did not occur, participants were censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day. |
| Overall Response Rate (ORR) (Safety Expansion Cohort) | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. |
| Time to First Response | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Time to first response was defined as the number of days from the date of first dose to the date of the first sign of response (CR, CRi, nPR, or PR) given the participant has had a CR, CRi, confirmed nPR, or confirmed PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. The first response could have been an assessment by physical exam as long as the results were later confirmed per the 2008 Modified IWCLL NCI-WG criteria. For participants who never experienced a response, the participant's data were not included in the analysis. |
| Time to 50% Reduction in Absolute Lymphocyte Count | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Time to 50% reduction in absolute lymphocyte count (ALC) was defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC had reduced to 50% of the baseline value. Only participants with a baseline of ALC \> 5 × 10\^9 /L were included in the analysis. For participants who never achieved a 50% reduction in ALC, the participant's data were not included in the analysis. |
| Overall Survival | Up to the data cutoff date of 15 December 2020, approximately 7.5 years of follow-up | Overall survival (OS) was defined as number of days from the date of first dose to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. |
| Percentage of Participants Who Moved on to Stem Cell Transplant | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | The percentage of participants who moved on to stem cell transplant was summarized. |
| Time to Progression | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Time to progression (TTP) was defined as the number of days from the date of first dose to the date of earliest disease progression. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant did not experience disease progression, then the data was censored at the date of last available disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day. |
| Complete Remission (CR) Rate | Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up | Complete remission was defined as the proportion of participants who achieved a CR or Complete Remission with Incomplete Marrow Recovery(CRi ) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a CR or CRi were considered to be non-responders in the calculation of CR rate. |
Countries
Australia, Canada, France, Germany, Poland, United Kingdom, United States
Participant flow
Pre-assignment details
All treated participants: all participants who received at least one dose of ABT-199 in either the Main Cohort or Safety Expansion Cohort
Participants by arm
| Arm | Count |
|---|---|
| Main Cohort Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. | 107 |
| Safety Expansion Cohort Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg. | 51 |
| Total | 158 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse event- not related to progression | 18 | 5 |
| Overall Study | Adverse event- related to progression | 7 | 2 |
| Overall Study | COVID-19 logistical restrictions | 1 | 0 |
| Overall Study | Investigator request | 1 | 1 |
| Overall Study | Other, not specified | 18 | 15 |
| Overall Study | Progressive disease per protocol | 46 | 17 |
| Overall Study | Progressive disease- Richter's | 12 | 7 |
| Overall Study | Stem cell transplant | 2 | 1 |
| Overall Study | Withdrew consent | 2 | 3 |
Baseline characteristics
| Characteristic | Main Cohort | Safety Expansion Cohort | Total |
|---|---|---|---|
| Age, Continuous | 65.7 years STANDARD_DEVIATION 9.87 | 65.4 years STANDARD_DEVIATION 9.97 | 65.6 years STANDARD_DEVIATION 9.87 |
| Race/Ethnicity, Customized American Indian/Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Black | 3 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized MISSING | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Multi race | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White | 103 Participants | 49 Participants | 152 Participants |
| Sex: Female, Male Female | 37 Participants | 22 Participants | 59 Participants |
| Sex: Female, Male Male | 70 Participants | 29 Participants | 99 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 62 / 107 | 19 / 51 |
| other Total, other adverse events | 103 / 107 | 50 / 51 |
| serious Total, serious adverse events | 78 / 107 | 34 / 51 |
Outcome results
Primary
Number of Participants With Adverse Events (Safety Expansion Cohort)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From the first dose of study drug until 30 days following last dose of study drug (up to 69 months)
Population: All treated participants in the Safety Expansion Cohort
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Main Cohort | Number of Participants With Adverse Events (Safety Expansion Cohort) | 51 Participants |
Primary
Overall Response Rate (Main Cohort)
The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria as assessed by the Independent Review Committee (IRC) in the first 70 participants treated in the Main Cohort.
Time frame: Up to 36 weeks
Population: The first 70 participants who were treated with ABT-199 in the Main Cohort
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Main Cohort | Overall Response Rate (Main Cohort) | 77.1 percentage of participants |
Comparison: The ORR for ABT-199 was tested to reject the null hypothesis of ORR = 40%. If the null hypothesis is rejected and the ORR is higher than 40%, then ABT-199 has been shown to have an ORR significantly higher than 40%.The p-value is from the exact binomial distribution comparing ABT-199 ORR to the 40% historical control rate.p-value: <0.001Clopper-Pearson exact method
Secondary
Complete Remission (CR) Rate
Complete remission was defined as the proportion of participants who achieved a CR or Complete Remission with Incomplete Marrow Recovery(CRi ) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a CR or CRi were considered to be non-responders in the calculation of CR rate.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Main Cohort | Complete Remission (CR) Rate | 21.5 percentage of participants |
| Safety Expansion Cohort | Complete Remission (CR) Rate | 27.5 percentage of participants |
Secondary
Duration of Overall Response
Duration of overall response (DoR) was defined as the number of days from the date of first response (CR, CRi, nPR, or PR) by either CT scan or physical exam determination to the earliest recurrence (progressive disease; PD) or death. For participants who had a PR before CR, CRi, or nPR in subsequent visits, the DoR was computed from the earliest PR. If a participant was still responding, then their data was censored at the date of their last available disease assessment. To be included in the DoR analysis, participants must have had a response per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria (CR, CRi, confirmed nPR, or confirmed PR). For participants who never experienced response, their data was not included in the analysis.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort with a response and available data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Cohort | Duration of Overall Response | 35.3 months |
| Safety Expansion Cohort | Duration of Overall Response | NA months |
Secondary
Event-free Survival
Event-free survival (EFS) was defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy. If the specified event (disease progression, death, start of a new anti-leukemic treatment) did not occur, participants were censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort with available data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Cohort | Event-free Survival | 24.7 months |
| Safety Expansion Cohort | Event-free Survival | 30.2 months |
Secondary
Overall Response Rate (ORR) (Safety Expansion Cohort)
The overall response rate (ORR) is defined as the proportion of participants with an overall response (complete remission \[CR\] + complete remission with incomplete marrow recovery \[CRi\] + nodular partial remission \[nPR\] + partial remission \[PR\]) per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Safety Expansion Cohort
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Main Cohort | Overall Response Rate (ORR) (Safety Expansion Cohort) | 82.4 percentage of participants |
Secondary
Overall Survival
Overall survival (OS) was defined as number of days from the date of first dose to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later.
Time frame: Up to the data cutoff date of 15 December 2020, approximately 7.5 years of follow-up
Population: All treated participants with available data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Cohort | Overall Survival | 53.4 months |
| Safety Expansion Cohort | Overall Survival | NA months |
Secondary
Partial Remission (PR) Rate
PR rate was defined as the proportion of participants who achieved a nodular partial remission (nPR) or PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. Participants who did not achieve a nPR or PR were considered to be non-responders in the calculation of PR rate.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Main Cohort | Partial Remission (PR) Rate | 53.3 percentage of participants |
| Safety Expansion Cohort | Partial Remission (PR) Rate | 54.9 percentage of participants |
Secondary
Percentage of Participants Who Moved on to Stem Cell Transplant
The percentage of participants who moved on to stem cell transplant was summarized.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants with available data
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Main Cohort | Percentage of Participants Who Moved on to Stem Cell Transplant | 2.8 percentage of participants |
| Safety Expansion Cohort | Percentage of Participants Who Moved on to Stem Cell Transplant | 2.5 percentage of participants |
Secondary
Progression-free Survival
Duration of progression-free survival (PFS) was defined as the number of days from the date of first dose to the date of earliest disease progression or death. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant does not experience disease progression or death, then the data was censored at the date of last disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort with available data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Cohort | Progression-free Survival | 24.7 months |
| Safety Expansion Cohort | Progression-free Survival | 30.2 months |
Secondary
Time to 50% Reduction in Absolute Lymphocyte Count
Time to 50% reduction in absolute lymphocyte count (ALC) was defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC had reduced to 50% of the baseline value. Only participants with a baseline of ALC \> 5 × 10\^9 /L were included in the analysis. For participants who never achieved a 50% reduction in ALC, the participant's data were not included in the analysis.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants with a baseline of ALC \> 5 × 10\^9 /L, a 50% reduction in ALC, and available data
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Main Cohort | Time to 50% Reduction in Absolute Lymphocyte Count | 1.1 weeks |
| Safety Expansion Cohort | Time to 50% Reduction in Absolute Lymphocyte Count | 1.2 weeks |
Secondary
Time to First Response
Time to first response was defined as the number of days from the date of first dose to the date of the first sign of response (CR, CRi, nPR, or PR) given the participant has had a CR, CRi, confirmed nPR, or confirmed PR per the 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL)/National Cancer Institute-Working Group (NCI-CWG) criteria. The first response could have been an assessment by physical exam as long as the results were later confirmed per the 2008 Modified IWCLL NCI-WG criteria. For participants who never experienced a response, the participant's data were not included in the analysis.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort with a response and available data
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Main Cohort | Time to First Response | 1.1 months |
| Safety Expansion Cohort | Time to First Response | 1.3 months |
Secondary
Time to Progression
Time to progression (TTP) was defined as the number of days from the date of first dose to the date of earliest disease progression. All disease progression was included regardless of whether the event occurred while the participant was taking ABT-199 or had previously discontinued ABT-199. If the participant did not experience disease progression, then the data was censored at the date of last available disease assessment. Data for participants without any disease assessments performed after the baseline visit were censored at the date of first dose plus 1 day.
Time frame: Up to the data cutoff date of 15 June 2017, approximately 4 years of follow-up
Population: All treated participants in the Main Cohort and the Safety Expansion Cohort with available data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Main Cohort | Time to Progression | 28.2 months |
| Safety Expansion Cohort | Time to Progression | 30.2 months |